REGENXBIO Announces Presentations at the 20th Annual WORLDSymposium 2024
ROCKVILLE, Md., Jan. 31, 2024 /PRNewswire/ — REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations on its program for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, will be shared at the 20th Annual WORLDSymposium™ 2024, taking place in San Diego, CA February 3-9, 2024.
Related news for (RGNX)
- REGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE® Trial of RGX-121 for Treatment of MPS II
- REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II
- REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy
- REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights
- REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy